Table 2.

Outcome measure timepoints

Item	Scale/test	Baseline	Week 10	Week 20
Main study*
Demographics	–	X	–	–
Patient activation	PAM-13	X	X	X
Knowledge	CKD-SMKT	X	X	X
Health status	SF-12	X	X	X
Symptoms	KSQ	X	X	X
Sarcopenia	SARC-F	X	X	X
Illness perception	IPQ-R	X	X	X
Physical activity	GPPAQ	X	X	X
Diet	UKDDQ	X	X	X
Medication adherence	MARS-5	X	X	X
Healthcare use	EPQ	X	X	X
Physical function	STS-60	X	X	X
Clinical data	Full blood count, U&Es	X	X	X
Substudy†
Anthropometry	Height, weight, BMI, waist and hip circumference	X	X	X
Muscle phenotyping	BIA, ultrasonography	X	X	X
Physical function	Gait speed, HGS, STS-60, TUAG	X	X	X
Physical activity	Accelerometery (7 days)	X	X	X
Qualitative component	Semistructured interview	X	X	X

*Main study outcomes delivered online to all patients.

†Substudy outcomes assessed in a subset of patients. Qualitative interviews may be performed at any of the timepoints depending on participants’ voluntary participation and/or their status in the study.

BIA, bioelectrical impendence analysis; BMI, body mass index; CKD-SMKT, Chronic Kidney Disease Self-Management Knowledge Tool; EPQ, Modified Economic Patient Questionnaire; GPPAQ, General Practice Physical Activity Questionnaire; HGS, handgrip strength; IPQ-R, Illness Representations Questionnaire (Brief); KSQ, Kidney Symptom Questionnaire; MARS-5, Medication Adherence Report Scale; PAM-13, Patient Activation Measure; SF-12, 12 Item Short Form Health Survey; STS-60, Sit-to-stand-60; TUAG, Timed-up-and-go’ test; U&Es, Urea and electrolytes; UKDDQ, UK Diabetes and Diet Questionnaire.